JCOGの基本情報 > 研究実績 > 泌尿器科腫瘍グループ

JCOGの基本情報泌尿器科腫瘍グループ

更新日:2015年11月27日

  1. 論文
    1. 委員会承認の治療研究
      F Kunieda, H Kitamura, M Niwakawa, et al.: Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection; Japan Clinical Oncology Group Study JCOG 1019. Jpn J Clin Oncol. 42: 1094-1098, 2012. (PMID: 22952293)
      H Kitamura, T Tsukamoto, T Shibata, et al.: Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group study JCOG0209. Ann Oncol. 25(6): 1192-1198, 2014. (PMID: 24669010)
    2. グループ代表者管理の治療研究
      A Yokomizo, K Tobisu, H Kawamoto, et al.: Randomized Controlled Trial to Evaluate Radiation plus Endocrine Therapy or Endocrine Therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 35: 34-36, 2005.
      Y Matsui, H Nishiyama, O Ogawa, et al.: The current status of perioperative chemotherapy for invasive bladder cancer : a multiinstitutional retrospective study in Japan. Int J Clin Oncol, 10: 133-138, 2005.
      K Kawamoto, H Enokida, M Nakagawa, et al.: p16 (INK4a) and p14 (ARF) methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun. 339: 790-796, 2006.
      I Honma, N Masumori, T Tsukamoto, et al.: Removal of more lymph nodes may provide a better outcome as well as more accurate pathology in patients with bladder cancer-An analysis of the role of pelvic lymph node dissection. Urology. 68: 543-548, 2006.
      A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen(PSA) level, pT and Gieason score as predictors of PSA recurrence after radical prostatectomy; a multi-institution outcome study in Japan. BJU Int. 98: 549-553, 2006.
      Y Kakehi, T Kamoto, T Shiraishi, et al.: Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1c N0 M0 Prostate Cancer. Jpn J Clin Oncol. 38(2): 122-128, 2008.
      T Shindo, N Masumori, F Fukuta, et al.: Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease? Jpn J Clin Oncol. 40: 153-156, 2010.
      K Kuroiwa, T Shiraishi, O Ogawa, et al.: for the Clinicopathological Research Group for Localized Prostate Cancer Investigators: Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol. 183(3): 952-957, 2010.
      H Koga, S Ozono, T Tsushima, et al.: BCG Tokyo Strain Study Group: Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol. 17(9): 759-767, 2010.
      S Hinotsu, H Akaza, S Naito, et al.: Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence? free survival following transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. BJU Int. 108: 187-193, 2011.
      T Maeda, E Kikuchi, K Matsumoto, et al.: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J Urol. 185: 802-806, 2011.
      S Sakano, H Matsuyama, et al.: Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines. BJU Int. 107: 1598-1604, 2011.
      K Yuge, E Kikuchi, K Matsumoto, et al.: Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy. Jpn J Clin Oncol. 41: 565-570, 2011.
      H Kitamura, K Taguchi, Y Kunishima, et al.: Paclitaxel, ifosmide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phse II study of the SUOC group. Cancer Sci. 102: 1171-1175, 2011.
      H Tsuruta, T Inoue, S Narita, et al.: Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma. Int J Clin Oncol. 16: 533-538, 2011.
      M Ikeda, K Matsumoto, K Tabata, et al.: Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Jpn J Clin Oncol. 41: 1214-1220, 2011.
      M Sugimoto, T Shiraishi, H Tsunemori, et al.: Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol. 40(10): 973-979, 2010.
      Y Sumiyoshi, K Hashine, Y Kakehi, et al.: Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: a phase II study. Jpn J Clin Oncol. 40(10): 967-972, 2010.
      F Fukuta, N Masumori, I Honma, et al.: Clinical Outcomes of Patients with pT0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience. Jpn J Clin Oncol. 41: 115-120, 2011. (PMID: 20696818)
      M Bul, X Zhu, R Valdagni, et al.: Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 63(4): 597-603, Apr 2013.
      H Hirama, M Sugimoto, K Ito, et al.: The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol. 140(2): 257-263, Feb 2014.
      M Sugimoto, H Hirama, A Yamaguchi, et al.: Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. PRIAS-JAPAN study group. World J Urol. 33(7): 981-987, Jul 2015.
      S Loeb, SM Bruinsma, J Nicholson, et al.: Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur Urol. 67(4): 619-626, Apr 2015.
      LP Bokhorst, AR Alberts, A Rannikko, et al.: Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. PRIAS study group. Eur Urol. 29 Jun 2015.
      H Kitamura, F Takei, S Nishida, et al.: Lymph node metastasis mapping in extended lymphadenectomy to the level of the inferior mesenteric artery for bladder cancer. Int J Clin Oncol. 17: 63-68, 2012.
      K Ichihara, H Kitamura, N Masumori, et al.: Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in patients with bladder cancer. Int J Clin Oncol. 18: 75-80, 2013.
      N Nishiyama, H Kitamura, M Mutoh, et al.: Clinicopathological analysis of patients with nonmuscle-invasive bladder cancer who underwent radical cystectomy. Surg Sci. 3: 347-352, 2012.
      進藤哲哉、北村 寛、舛森直哉、他: 尿路上皮癌に対する術前化学療法としてのGC療法の近接効果に関する検討. 泌尿紀要. 58: 391-394, 2012.
      H Kitamura, M Igarashi, T Tanaka, et al.: A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. Jpn J Clin Oncol. 42(12): 1192-1196, 2012.
      T Shindo, N Masumori, K Kobayashi, et al.: Long-term outcome of small, organ-confined renal cell carcinoma is not always favorable. BJU Int. 111: 941-945, 2013.
      K Ichihara, N Masumori, H Kitamura, et al.: Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens. Int J Clin Oncol. 19(1): 152-156, 2014.
      Y Kyoda, K Kobayashi, M Hirobe, et al.: Evaluation of long-term outcome for patients with renal cell carcinoma after surgery: analysis of cancer deaths occurring more than 10 years after initial treatment. Int J Clin Oncol. 14: 146-151, 2014.
      N Nishiyama, H Kitamura, T Maeda, et al.: Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol. 43(11): 1124-1131, 2013.
      H Kitamura, T Maeda, T Tanaka, et al.: Comparison of laparoscopic, hand-assisted, and open nephroureterectomy. JSLS. 18(2): 288-293, 2014.
      T Shindo, N Masumori, H Kitamura, et al.: Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol. 32(5): 1281-1285, 2014.
      T Abe, H Kitamura, W Obara, et al.: Outcome of metastasectomy for urothelial carcinoma: A multi-institutional retrospective study in Japan. J Urol. 191: 932-936, 2014.
      N Nishiyama, H Kitamura, H Hotta, et al.: Construction of predictive models for cancer-specific survival of patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study. Jpn J Clin Oncol. 44(11): 1101-1108, 2014.
      K Hashimoto, T Mizuno, H Kitamura, et al.: The primary local stage at diagnosis predicts regional symptoms caused by progression in patients with castration-resistant prostate cancer. Urology. 85(2): 430-435, 2015.
      F Fukuta, H Kitamura, M Yanase, et al.: Efficacy and safety of docetaxel and prednisone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Jpn J Clin Oncol. 45(7): 682-687, 2015.
      井上隆太、北村 寛、進藤哲哉、他: 転移性淡明腎細胞癌に対する分子標的薬の効果と予後因子の検討. 泌尿紀要. 61(4): 135-139, 2015.
      栗村雄一郎、高橋 聡、桧山佳樹、他: 泌尿器科領域抗癌化学療法中の発熱に対するプロカルシトニン測定の意義. 泌尿紀要. 61(4): 141-145, 2015.
      H Kitamura, A Takahashi, H Hotta, et al.: Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients. Int J Urol. in press, 2015.
      G Sonpavde, GR Pond, TK Choueiri, et al.: Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol. in press, 2015.
      T Inoue, H Kinoshita, N Terada, et al.: Evaluation of prognostic factors after radical prostatectomy in pT3b prostate cancer patients in Japanese population. Jpn J Clin Oncol. 45:780-784, 2015.
      Y Matsui, H Nishiyama, K Yoshimura, et al.: The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers. Int J Clin Oncol. 18:321-828, 2013.
    3. 附随研究等
      X Wu, Y Kakehi, et al.: Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: comparison with cytokeratin 20. J Urol. 174: 2138-2143, 2005.
      A Yokomizo, M Murai, S Baba, et al.: Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int. 98: 549-553, 2006.
      N Nishiyama, E Arai, R Nagashio, et al.: Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations. Carcinogenesis. 32: 462-469, 2011.
      H Okazoe, X Zhang, D Liu, et al.: Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder. Int J Mol Sci. 14(6): 12367-12379, 2013.
      SM Ahmed, X Wu, X Jin, et al.: Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 33(2): 566-572, 2015.
      N Kamiya, H Suzuki, T Ueda, et al.: Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. Int J Clin Oncol. 19(1): 157-164, 2014.
      T Sazuka, T Imamoto, T Namekawa, et al.: (2013) Analysis of preoperative detection for apex prostate cancer by transrectal biopsy. Prostate Cancer. 2013.
      S Kamada, S Sakamoto, K Ando, et al.: Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. J Urol. pii: S0022-5347(15), 2015.
    4. 総説・解説
      S Naito: Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer. Jpn J Clin Oncol. 35: 365-374, 2005.
      H Kitamura, T Tsukamoto: Early bladder cancer: concept, diagnosis,and management. Int J Clin Oncol. 11: 28-37, 2006.
      塚本泰司、前田俊浩、福多史昌: 筋層浸潤膀胱癌におけるneoadjuvant chemotherapyの意義. 泌尿器外科. 20: 1137-1145, 2007.
      筧 善行: 特集 リスクで考える前立腺癌治療 リスクで考える各種治療法の適応と限界 PSA監視療法. Urology View. 8(2): 27-32, 2010.
      横溝 晃、内藤誠二: 前立腺がん根治術後再発に対する治療. 臨牀と研究. 88(11): 1398-1402, 2011.
      Y Kakehi. Re: Prostate cancer antigen 3 score accurately predicts tumor volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 60: 178-179, 2011.
      Y Kakehi: Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes. Asian J Androl. 14(3): 361-364, 2012.
      M Sugimoto, Y Kakehi: Updated results from the European Randomized Study of prostate-specific antigen (PSA) screening for prostate cancer: are Asian countries encouraged to promote PSA screening? Asian J Androl. 14(4): 522-524, 2012.
      北村 寛: 膀胱がんに対する術前補助化学療法の意義は?. 臨床腫瘍プラクティス. 8: 155-158, 2012.
      H Kitamura, Y Kakehi: Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?. Jpn J Clin Oncol. 45(4): 315-322, 2015.
      MB Amin, SC Smith, VE Reuter, , et al.: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol. 28: 612-630, 2015.
      T Tsuzuki, Intraductal carcinoma of the prostate: a comprehensive and updated review. Int J Urol. 22: 140-145, 2015.
      北村 寛、舛森直哉: 尿路上皮癌に対する治療の最前線. 細胞. 45: 654-657, 2013.
      北村 寛、舛森直哉: 腹腔鏡下腎尿管全摘除術後の予後因子:膀胱内再発を含めて. Jpn J Endourol. 27(2): 258-261, 2014.
      H Kitamura, Y Kakehi: Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR? Jpn J Clin Oncol. 45(4): 315-322, 2015.
      北村 寛: 術前化学療法の現況. MVACによるneoadjuvant chemotherapy. 泌尿器外科. 28(3): 255-258, 2015.
      北村 寛、舛森直哉: 【高齢者の泌尿器癌】腎細胞癌. 腎と透析. 78(6): 910-915, 2015.
  2. 主な学会発表
    1. 委員会承認の治療研究
      横溝 晃、古賀寛史、此元竜雄、他: 早期前立腺がんにおける根治術後の再発に関するoutcome study. 第41回日本癌治療学会総会. 2003年10月.
      塚本泰司、他: 筋層浸潤癌に対する根治的膀胱摘除の手術所見と術後早期合併症の検討-JCOG 0209試験の結果-. 第49回日本癌治療学会学術集会. 2011年10月.
      北村 寛、塚本泰司、舛森直哉、他: 筋層浸潤性膀胱癌に対する術前MVAC療法後の病理所見-JCOG0209試験. 第50回日本癌治療学会学術総会. 2012年10月.
      H Kitamura, T Tsukamoto, N Masumori, et al.: Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for invasive bladder cancer (BC): Japan Clinical Oncology Group Study, JCOG0209. ASCO Genitourinary Cancers Symposium 2013, Feb 2013.
      H Kitamura, T Tsukamoto, N Masumori, et al.: Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group Study, JCOG0209. ASCO ’13 Annual Meeting, Jun 2013.
      二瓶圭二、横溝 晃、内藤誠二、他: JCOG0401前立腺癌術後PSA再発臨床試験における放射線治療QA. 第25回日本放射線腫瘍学会. 2012年11月.
      J Inokuchi, K Kuroiwa, Y Kakehi, et al.: The therapeutic impact of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial carcinoma: multi-institutional case series study JCOG1110-A. EAU15, March 2015.
      K Kuroiwa, J Inokuchi, Y Kakehi, et al.: Impact of previous, simultaneous or subsequent bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: multi-institutional case series study JCOG1110-A. EAU15, March 2015.
      猪口淳一、黒岩顕太郎、筧 善行、他: 根治手術が実施された上部尿路癌におけるリンパ節郭清術の意義に関する検討-JCOG1110-A研究より. 第103回日本泌尿器科学会総会. 2015年4月.
      黒岩顕太郎、猪口淳一、筧 善行、他: 根治手術が実施された上部尿路癌における術後膀胱内再発に関する検討-JCOG1110-A研究より. 第103回日本泌尿器科学会総会. 2015年4月.
    2. グループ代表者管理の治療研究
      S Naito: Treatment of Patients with PSA Recurrence after Radical Prostatectomy. The 18th International Symposium of Foundation for Promotion of Cancer Research. Jan 2005.
      Y Kakehi, T Kamoto, T Shiraisi, et al.: PSA doubling time assessment based upon 4 consecutive measurements for 6 months: Is it a realistic strategy to spare over-treatment for patients with stage T1c prostate cancer presenting favorable biopsy features? Annual American Urological Association Meeting. May 2006.
      横溝 晃、古賀寛史、鳶巣賢一、他: 日本の早期前立腺がん根治手術後の再発に関するアウトカム研究 第93回日本泌尿器科学会総会. 2005年4月.
      M Sugimoto, T Shiraishi, H Tsunemori, et al.: Predictability of PSA doubling time for unfavorable pathology at radical prostatectomy: Results from a prospective Japanese active surveillance cohort. EAU Annual Congress. Mar 2011.
      M Sugimoto, H Hirama, Y Kakehi, PRIAS-JAPAN Study Group: Evaluation of prostate re-biopsy outcomes and change in QOL status at 1-year after active surveillance in Japanese prostate cancer patients-From a Japanese AS study and the PRIAS-JAPAN-. EAU Annual Congress. Mar 2012.
      M Sugimoto, H Hirama, Y Kakehi, et al.: 前立腺癌PSA監視療法における1年目の再生検の結果とQOLの変化について. -日本の2つの多施設前向き研究での検討-. 第10回日本臨床腫瘍学会. 2012年7月.
      杉元幹史、平間裕美、上田修史、他: PSA監視療法中の1年目再生検における病理所見悪化予測因子の検討 -PRIAS-JAPAN-. 第101回日本泌尿器科学会総会. 2013年4月.
    3. 附随研究等
      なし
    4. 総説・解説
      なし
トップへ戻る